First Trust Nasdaq Transportation ETF (NASDAQ: FTXR)

Ultime notizie per First Trust Nasdaq Transportation ETF (NASDAQ:FTXR)

First Trust Nasdaq Transportation ETF

Industrials

Consumer Cyclical

Energy

The Fund will normally invest at least 90 percent of its net assets (including investment borrowings) in the securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Index is owned and is developed, maintained and sponsored by Nasdaq, Inc. (the Index Provider). The Index Provider may, from time to time, exercise reasonable discretion as it deems appropriate in order to ensure Index integrity.

Fedex Corp.

Tesla, Inc.

Escrow Account Long Term

United Parcel Service Inc

Ford Motor Company

United Rentals Inc.

Union Pacific Corp

Delta Air Lines Inc.

Csx Corp.

United Airlines Holdings Inc.

Paccar Inc.

Norfolk Southern Corp.

Jim Cramer Weighs In On Friday’s White House Drama And Its Market Impact

Analyst Color

Equities

Government

Market Summary

News

Economics

Markets

BABA

DRIV

FTXR

IDRV

STLA

Cosa significano le nuove tariffe per case auto, fornitori e investitori? L&#39;esperto Jim Cramer svela strategie per proteggere il portafoglio.

Jim Cramer analizza l&#39;impatto dei dazi sull&#39;industria automobilistica

While the ‘Oracle of Omaha,' Warren Buffett, has offloaded more than two-thirds of Berkshire Hathaway Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) stake in the iPhone maker, he has built a stake in this consumer-facing company over the last three quarters.
Check out the current price of <a href="https://www.benzinga.com/quote/AAPL">AAPL</a> stock and <a href="https://www.benzinga.com/quote/DPZ">DPZ</a> stock here. 
What Happened: According to its 13F filings, Berkshire holds 300 million shares of a total of 26% stake in Tim Cook's Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) as of the end of the first quarter of 2025.
This is down by two-thirds or 67.25% of Berkshire's Apple stake, which stood at 916 million shares during the third quarter of 2023. Over approximately two years, the company has significantly offloaded about 616 million shares of its largest holding.
This contrasts with its stake in pizza maker Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>). Berkshire first acquired 1.3 million shares in the firm during the third quarter of 2024 and has increased its holdings by 100% to 2.6 million shares as of the first quarter of 2025.
The table below showcases Berkshire's historical trades in Apple and Domino's over the last few quarters.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Company</td>
<td>Holdings As Of Q3 2023</td>
<td>Holdings As Of Q4 2023</td>
<td>Holdings As Of Q1 2024</td>
<td>Holdings As Of Q2 2024</td>
<td>Holdings As Of Q3 2024</td>
<td>Holdings As Of Q4 2024</td>
<td>Holdings As Of Q1 2025</td>
<td>Value As Of Q1 2025</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>916 million</td>
<td>906 million</td>
<td>789 million</td>
<td>400 million</td>
<td>300 million</td>
<td>300 million</td>
<td>300 million</td>
<td>$66.639 billion</td>
</tr>
<tr>
<td>Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>)</td>
<td>&#8212;</td>
<td>&#8212;</td>
<td>&#8212;</td>
<td>&#8212;</td>
<td>1.3 million</td>
<td>2.4 million</td>
<td>2.6 million</td>
<td>$1.204 billion</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, looking at it on a quarter-on-quarter basis, Berkshire made no adjustments in its Apple holdings from the first quarter of 2024 to the first quarter of 2025. However, it bumped its stake in Domino's by 10%.
As of the end of the first quarter, Berkshire holds $66.639 billion worth of Apple shares and $1.204 billion worth of Domino's shares.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Company</td>
<td>Holdings (as of Dec. 31, 2024)</td>
<td>Holdings (as of March 31, 2025)</td>
<td>Change (in %)</td>
<td>Value (as of March 31, 2025)</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>300,000,000</td>
<td>300,000,000</td>
<td>0%</td>
<td>$66.639 billion</td>
</tr>
<tr>
<td>Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>)</td>
<td>2,382,000</td>
<td>2,620,613</td>
<td>10%</td>
<td>$1.204 billion</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/ipos/25/07/46537119/figmas-market-debut-could-value-design-giant-at-16-billion-down-from-adobes-20-billion-deal">Figma&#8217;s Market Debut Could Value Design Giant At $16 Billion, Down From Adobe&#8217;s $20 Billion Deal</a>
Why It Matters: Apple has been facing regulatory hurdles concerning its iPhone manufacturing in China and India amid tariff turmoil. Whereas President Donald Trump's One Big, Beautiful Bill makes the 21% peak marginal corporate income tax rate permanent.
Meanwhile, Wall Street has been urging the company to make huge investments in <a href="https://www.benzinga.com/markets/equities/25/07/46439852/aapl-stock-would-soar-if-it-buys-this-says-jim-cramer-continued-buybacks-will-do-nothing">artificial intelligence (AI)</a> instead of using its cash pile to engage in its <a href="https://www.benzinga.com/content/42911057/the-3-kings-of-buybacks-in-2024-can-they-do-it-again">share repurchase program</a>. 
Domino's, on the other hand, stated during its second quarter earnings call that it believes its cost structure and scale uniquely position it to thrive as consumers increasingly <a href="https://www.benzinga.com/markets/earnings/25/07/46537951/dominos-is-built-for-a-value-war-its-crushing-competitors-with-margin-headroom-ad-firepower-industry-headwinds-are-tailwinds-for-us">prioritize value</a>, according to CEO Russell Weiner. 
Weiner stated that while value-seeking trends act as &#8220;headwinds&#8221; for competitors, they&#8217;re &#8220;tailwinds&#8221; for Domino&#8217;s, largely due to its integrated supply chains and strong franchise profitability.
Price Action: Shares of Apple were up 0.13% in premarket on Tuesday. It has fallen by 12.86% on a year-to-date basis and 5.13% over the past year.
DPZ was 0.49% higher in premarket on Tuesday. It has gained 6.28% YTD and 11.24% over the past here.
Benzinga Edge Stock Rankings shows that Domino&#8217;s had a weaker price trend over the medium and short term but a strong price trend over the long term. Its momentum ranking was good, but its value ranking was subpar at the 24.49th percentile.
The details for Apple's Edge Stock Rankings other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="153" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22070157/DPZ-EDGE-1024x153.png" alt="" class="wp-image-995200" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22070157/DPZ-EDGE-1024x153.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22070157/DPZ-EDGE-300x45.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22070157/DPZ-EDGE-768x115.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22070157/DPZ-EDGE.png 1164w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.10% at $628.14, while the QQQ declined 0.18% to $563.13, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46513468/bitcoin-miner-iren-could-surge-1572-as-sotp-valuation-pegs-300-target-hedge-fund-manager-eric-jackson-says-were-cooking-with-gas">Bitcoin Miner IREN Could Surge 1,572% As SOTP Valuation Pegs $300 Target — Hedge Fund Manager Eric Jackson Says, &#8216;We&#8217;re Cooking With Gas&#8217;</a></li>
</ul>
Photo Courtesy: Photo Agency on Shutterstock.com

AAPL

Warren Buffett Doubles His Stake In This Pizza-Maker Over 3 Quarters As Berkshire Sells Two-Thirds Of Its Apple Holdings

WIIM

CSX shares are trading higher on possible continued strength after TD Cowen upgraded the stock yesterday from Hold to Buy and raised its price target from $32 to $45.

SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>), a commercial-stage healthcare company, announced today positive preliminary results from the <a href="https://www.globenewswire.com/Tracker?data=xVSPUzoFSoUMEJF0mdDNX402dFF4T0zj1AOBiEfzNL2KjaDg2nfThvp2jIm1SJyFUNvv2htM7vgmyMG3stK0Ahbl46BMtlyL7M3L0CGCvvnDseDbb6b2pQ0jwDEHMaAuz-hAx8Tu8I6nnB5-cpQOk1uDC1-j9-n5N2_PRCLdbY8=">SAVE Surveillance Registry</a> which is assessing the use of the <a href="https://www.globenewswire.com/Tracker?data=w4wcNPx7NWD-AiXE1l8etGuCaIivEN0p7Ne7HIGqAmUxwVT7zGczhAuYfTOuvOTOYBzdMGP4p4cWrPVwoeLs30icu2hbRl5otqe6juY4P2iVwdaW6v09beclrlhR8vJ2">QUELIMMUNE therapy</a> in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). Based on the data collected from the first 20 pediatric patients in the SAVE Surveillance Registry, there were no device related safety events with the QUELIMMUNE therapy and 75% of patients have survived through 28 days. These new data are on track to validate or potentially exceed a 50% reduction in loss of life compared to historical data, as reported in <a href="https://www.globenewswire.com/Tracker?data=k1RKlDkcCSESM2g4K4J16cem4KXwR1oqn-h5XeLbuCdv0FI8X9BE3oNLo6gsYbYBNqpr9jnrD5fPokRStrxgZXvf4S3xrxGvFZ6--FpyY050KbWxbWLA8TqRW3ViDW-boGNiEjigAI-UhejBb0K1_qy5fhCNldokzMN1KqpZo3k=">Kidney Medicine</a>.
SeaStar also reported that additional analyses of the preliminary results of the SAVE Surveillance Registry are expected to mirror the clinical data that was submitted to the U.S. Food and Drug Administration (FDA) to support the approval of QUELIMMUNE under a Humanitarian Device Exemption. These data, including additional 60-day and 90-day survival results, as well as dialysis dependence outcomes, will be submitted as an abstract later this summer to a prominent pediatric nephrology conference taking place in the fall.
 &nbsp;

Biotech

General

SeaStar Medical Reports Early Results For QUELIMMUNE In Pediatric AKI And Sepsis, Showing 75% Survival And No Device-Related Safety Events

Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver disease).
The study, conducted at the Atlanta VA Medical Center, will benchmark daily GDNF injections against semaglutide in both standard diet-induced obese mice and human liver chimeric mouse models, a gold-standard translational platform.

HOTH

Hoth Therapeutics Announces CRADA With U.S. Department Of Veterans Affairs And FAVER To Evaluate GDNF As Metabolic Therapy Targeting Obesity And Hepatic Steatosis

Rosenblatt analyst Mike Genovese maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and raises the price target from $56 to $65.

Price Target

Analyst Ratings

CALX

Rosenblatt Maintains Buy on Calix, Raises Price Target to $65

Cathie Wood's ARK Invest has acquired $182 million of BMNR equity across multiple of its Funds, representing 4,773,444 common shares
100% of net proceeds of $177 million from ARK sale to be used to acquire ETH
Cathie Wood, MOZAYYX, Founders Fund, Pantera, Kraken, DCG, and Galaxy Digital support BitMine's goal of acquiring 5% of ETH
LAS VEGAS, July 22, 2025 /PRNewswire/ --&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) ("BitMine" or the "Company") today announced ARK Invest acquired 4,773,444 shares of BitMine common stock totalling $182 million. The Company expects to invest 100% of the net proceeds ($177 million) to acquire ETH. This transaction was accomplished via a block trade made in connection with the Company's previously announced ATM program.

BMNR

ARK Invest Acquires 4.77M Shares Of BitMine Common Stock Totalling $182M; Co Expects To Invest 100% Of Net Proceeds To Acquire ETH

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/07/21/final-trades-morgan-stanley-netflix-cognex-and-eqt-corp.html">Halftime Report Final Trades</a>,&#8221; Sarat Sethi, Managing Partner at DCLA, said Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported <a href="https://www.benzinga.com/quote/MS/earnings">great earnings.</a>
Morgan Stanley reported second-quarter 2025 earnings of $2.13 on July 16, up from $1.82 a year ago and exceeding the consensus estimate of $2.02. Net earnings increased to $3.54 billion from $3.08 billion. The U.S. bank reported revenue of $16.79 billion, up 12% year-over-year, beating the consensus estimate of $16.11 billion.
Stephen Weiss, Chief Investment Officer and Managing Partner of Short Hills Capital Partners, said Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) was unfairly penalized for the quarter. He still thinks it's a good opportunity.
Netflix, on July 17. reported second-quarter revenue of $11.08 billion, up 16% year-over-year. The revenue total beat a Street consensus estimate of $11.04 billion, according to data from Benzinga Pro. The company reported second-quarter earnings per share of $7.19, beating a Street consensus estimate of $7.06.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Amy Raskin, CIO at Chevy Chase Trust, named Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) as her final trade.
Lending support to her choice, Citigroup analyst Piyush Avasthy, on July 14, raised the price target on the stock from $30 to $37.
Joseph M. Terranova, Senior Managing Director for Virtus Investment Partners, picked EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>), which saw a sharp decline on Monday.
EQT will issue its second quarter financial and operating results news release after the closing bell on Tuesday, July 22.
Price Action:
<ul class="wp-block-list">
<li>Morgan Stanley shares fell 0.3% to close at $140.47 on Monday.</li>
<li>Netflix shares dipped 5.1% to settle at $1,209.24 during the session.</li>
<li>Cognex shares fell 1% to close at $33.73 during the session.</li>
<li>EQT shares tumbled 9.6% to settle at $53.54 on Monday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

Trading Ideas

CGNX

NFLX

Morgan Stanley, Netflix, Cognex And An Energy Stock: CNBC's 'Final Trades'

Guggenheim analyst Curry Baker maintains Liberty Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONA#NASDAQ">FWONA</a>) with a Buy and raises the price target from $95 to $110.

FWONA

Guggenheim Maintains Buy on Liberty Media, Raises Price Target to $110

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is entering a phase <a href="https://www.benzinga.com/money/bitcoin-price-prediction">of technical consolidation</a> while maintaining strong upside momentum, according to new insights from Glassnode and Fairlead Strategies.
What Happened: Analysts suggest that recent price action reflects a constructive setup for further gains, particularly over a multi-month horizon.
Bitcoin traded around $118,800 on Tuesday morning, after briefly touching a new all-time high above $123,000 on July 14.
Despite a slight pullback, both on-chain and technical indicators signal continued investor confidence and robust capital flows. 
Fairlead Strategies, in their July 21 outlook, identified a "measured move" target of $134,500 in the intermediate term, citing supportive long-term momentum and a breakout from prior resistance levels.
"The long-term momentum has reaccelerated with the breakout," Fairlead wrote, noting that short- and intermediate-term indicators remain firmly bullish. 
The technical support zone is now established near $108,300, giving traders a foundation to interpret near-term volatility within a broader upward structure.
Glassnode's report on Tuesday reinforced this view, highlighting strong realized capital flows and healthy speculative participation. 
Also Read: <a href="https://www.benzinga.com/markets/25/07/46535957/ethereum-roars-to-3-800-whats-driving-the-surge">Ethereum Roars To $3,800: What&#8217;s Driving The Surge?</a>
Profitability metrics remain elevated, although slightly cooling, suggesting a market still in the euphoric phase but beginning to de-risk.
Spot market activity showed some signs of profit-taking, with RSI retreating from overheated levels and cumulative volume delta (CVD) turning negative.
Nevertheless, elevated spot volumes point to ongoing market engagement. In derivatives markets, surging open interest and funding rates suggest speculative appetite remains high, though hedging activity is on the rise.
Why It Matters: The ETF market also reflected strength. U.S.-listed Bitcoin spot ETFs posted increased inflows and trading volumes, signaling sustained institutional demand despite a slight dip in MVRV ratios as investors begin realizing gains.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and altcoins also showed strength, with Fairlead's analysis indicating that Ethereum could approach the $4,000 level by the end of Q3, buoyed by favorable technicals and improved relative strength versus Bitcoin.
Altcoins such as Avalanche (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>), Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) all registered positive momentum shifts relative to Bitcoin on the 12-week Relative Rotation Graph.
The broader altcoin market is entering a bullish phase, Fairlead noted, with an equal-weight index showing a weekly MACD buy signal for the first time since before the 2024 post-election rally.
For now, analysts see the current environment as balanced, with sufficient long-term holder confidence and a maturing regulatory backdrop providing stability for potential upside follow-through.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46528570/is-1m-bitcoin-realistic-tom-lee-says-it-may-be-closer-than-you-think">Is $1M Bitcoin Realistic? Tom Lee Says It May Be Closer Than You Think</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AVAX

$BTC

$ETH

$LINK

$SOL

$XRP

Ethereum, Solana, XRP Outpace Bitcoin: Is The Altcoin Trade Here To Stay?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Philip Gibbs upgraded the rating for Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) from Sector Weight to Overweight and announced a $14 price target. Cleveland-Cliffs shares closed at $10.66 on Monday. <a href="https://www.benzinga.com/quote/clf/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Chiaverini upgraded Zions Bancorporation, National Association (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) from Underperform to Hold and raised the price target from $45 to $60. Zions Bancorp shares closed at $56.59 on Monday. <a href="https://www.benzinga.com/quote/zion/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Louie DiPalma upgraded the rating for Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Market Perform to Outperform. Booz Allen Hamilton shares closed at $109.32 on Monday. <a href="https://www.benzinga.com/quote/bah/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Tristan Gerra upgraded STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Neutral to Outperform and raised the price target from $23 to $50. STMicroelectronics shares closed at $32.81 on Monday. <a href="https://www.benzinga.com/quote/stm/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying BAH stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/BAH/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22081301/image-303-1024x588.png" alt="" class="wp-image-995295" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22081301/image-303-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22081301/image-303-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22081301/image-303-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22081301/image-303.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

ZION

This Booz Allen Hamilton Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $13 price target.

ENLV

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro's cell-free XpressCF&#xAE; technology to precisely engineer ADCs with predefined attributes, as well as FDA's cutting-edge analytical capabilities to fully characterize these materials.
&nbsp;
As part of the collaboration, Sutro and the Office of Pharmaceutical Quality (OPQ) within the FDA Center for Drug Evaluation and Research (CDER) will jointly lead the study design and selection of target antigens, payload-linkers, and drug conjugation sites representative of both approved ADCs and those in development. The results will be published upon completion, and the insights gained from this collaboration are expected to enhance OPQ's ongoing research efforts aimed at bolstering the FDA's capacity for the analytical characterization of ADCs to enhance ADC quality assessments.

STRO

Sutro Biopharma Partners With FDA To Advance Standards And Analytics For Antibody Drug Conjugates Using XpressCF Technology

Earnings

ASRV

AmeriServ Financial Q2 EPS $(0.02), Same YoY, Sales $14.15M Up From $13.25M YoY

Guggenheim analyst Curry Baker maintains Liberty Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and raises the price target from $104 to $120.

FWONK

Guggenheim Maintains Buy on Liberty Media, Raises Price Target to $120

AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) will release earnings results for the second quarter, before the opening <a href="https://www.benzinga.com/quote/T/earnings">bell on Wednesday, July 23</a>.
Analysts expect the Dallas-based company to report quarterly earnings at 53 cents per share, down from 57 cents per share in the year-ago period. AT&amp;T projects to report quarterly revenue of $30.46 billion. It reported $29.8 billion the previous year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 16, Morgan Stanley analyst Simon Flannery maintained an Overweight rating for AT&amp;T. It also raised the price target from $31 to $32.
With the recent buzz around AT&amp;T, some investors may be eyeing potential gains from the company's dividends. As of now, AT&amp;T offers an annual dividend yield of 3.84%. That&#8217;s a quarterly dividend amount of 28 cents per share ($1.11 a year).
To figure out how to earn $500 monthly from AT&amp;T, start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by AT&amp;T's $1.11 dividend: $6,000 / $1.11 = 5,405 shares.
So, an investor would need to own approximately $147,989 worth of AT&amp;T, or 5,405 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.11 = 1,081 shares, or $29,598 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
T Price Action: Shares of AT&amp;T rose by 1.6% to close at $27.38 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Image: Shutterstock

Dividends

How To Earn $500 A Month From AT&T Stock Ahead Of Q2 Earnings

TotalEnergies and Emerson's Aspen Technology business have announced a strategic collaboration to deploy advanced digital technologies for the continuous, real-time collection of data from TotalEnergies' industrial sites. The objective is to harness the value of that data to enhance decision-making, specifically through the use of artificial intelligence (AI), and optimize operational efficiency, energy use and environmental performance at TotalEnergies sites worldwide, thereby continuing to supply more reliable and sustainable energy.
Leveraging data in real time…
Under the terms of the deal, TotalEnergies will roll out Emerson's AspenTech Inmation&#x2122; across its industrial sites worldwide. This industrial data fabric will continuously collect and centralize millions of real-time data points from TotalEnergies' facilities, providing secure and unified access to data across the organization.
The digital infrastructure, which also includes Emerson's advanced process control solutions, will subsequently allow TotalEnergies to deploy AI use cases.
...to improve industrial performance
This rollout is planned over a two-year period and will ultimately enable TotalEnergies to extract more value from its data by:
<ul>
<li>Accelerating the detection of anomalies and performance degradation;</li>
<li>Optimizing energy consumption;</li>
<li>Enhancing operational safety;</li>
<li>Speeding up the integration of AI into industrial processes.</li>
</ul>
"At TotalEnergies, digital technology is a key enabler of our transformation toward a more sustainable and efficient energy future. Our collaboration with Emerson demonstrates how advanced technologies such as Inmation help us optimize operations, reduce emissions, and generate long-term value. This collaboration is a sign of our intention to turn data and digital tech into the hallmarks of our facilities' industrial excellence," said Namita Shah, President of OneTech at TotalEnergies.
"Emerson's Aspen Technology business has worked with TotalEnergies for almost 30 years, and we're excited to continue our collaboration by supporting their operational and sustainability objectives with our digital technologies. The powerful combination of AI and our industrial data fabric solution will serve to accelerate TotalEnergies' mission," said Vincent Servello, President of Emerson's Aspen Technology business.
Emerson's Inmation technology is a key component of Emerson's recently announced <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4472557-1&amp;h=813117912&amp;u=https%3A%2F%2Fwww.emerson.com%2Fen-us%2Fnews%2F2025%2F05-emerson-project-beyond-to-modernize-and-seamlessly-integrate-the-industrial-automation-technology-stack&amp;a=Project+Beyond">Project Beyond</a>, the industry's first software-defined, OT-ready digital platform that seamlessly integrates and optimizes industrial operations to help customers enable Boundless Automation℠.

Contracts

TotalEnergies And Emerson Enters Strategic Collaboration To Deploy Advanced Digital Technologies For The Continuous, Real-Time Collection Of Data From TotalEnergies' Industrial Sites

D. Boral Capital analyst Jesse Sobelson maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $15 price target.

EVTL

D. Boral Capital Maintains Buy on Vertical Aerospace, Maintains $15 Price Target

Auburn National Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUBN#NASDAQ">AUBN</a>) reported quarterly earnings of $0.52 per share. This is a 4 percent increase over earnings of $0.50 per share from the same period last year. The company reported $8.133 million in sales this quarter. This is a 6.94 percent increase over sales of $7.605 million the same period last year.

AUBN

Auburn National Bancorp Q2 EPS $0.52 Up From $0.50 YoY, Sales $8.133M Up From $7.605M YoY

COMM

CommScope Announces Strategic Alliance With DvSum To Develop New Technology Solution, ServAssure NXT AI Platform Powered By DvSum

Offerings

IMNN

Imunon Files Prospectus To Register Additional $4.5M In Common Stock For At-the-Market Offering, Increasing Total To $10M

Comments

First Trust Nasdaq Transportation ETF

Notizie

Ultime notizie per First Trust Nasdaq Transportation ETF (NASDAQ:FTXR)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO